Visit our new website

Dear all,

I wanted to let you know that we released a new version of our corporate website today. Our new website offers insight into the growing sector of bioelectronic medicine, a rapidly emerging field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of challenging diseases. We previously stated that we aim to play a vital role in the emerging industry due to our core competency in advanced biomedical signal processing. To remind, our first product, PURE EP System, is a novel signal acquisition and processing technology aimed at addressing unmet clinical needs in the fast-growing market of arrhythmia, or irregular heartbeat, treatments. The PURE EP System aims to minimize noise and artifacts, which are present in the electrocardiographic and intracardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures. 

BioSig also dedicated a page to the Company’s strategic partnerships, from the clinical collaboration with Mayo Clinic to intellectual property strategy, which is architected by Silicon Valley-based Sherpa Technology Group and executed by the biomedical and technology experts at Sterne, Kessler, Goldstein & Fox, to the PURE EP System’s hardware and software development by Minnetronix Medical

The new website will also guide you through the collective skillset of Company’s leadership, covering medical technology industry knowledge, success in building strong businesses, intellectual property and robust capital markets expertise. Our Fortune 100 Board of Directors and Advisory Boards comprise of leaders from some of the largest and most influential companies, including Johnson & Johnson, Nasdaq and Wilmington Trust, and leading public organizations, such as U.S. Advisory Commission on Public Diplomacy. 

As BioSig approaches its 10-year anniversary, we wanted to transmit our broader vision and highlight our biggest assets: our human talent and our unique technological value proposition. We are convinced that it’s these two elements, which set BioSig up for the long-term success and value creation for the medical community and all of our shareholders.

We hope that you take a moment to visit our website. We always welcome your comments and thoughts. Do not hesitate to reach out to us on

With best wishes for a wonderful festive season. 

Kind Regards,  

Ken Londoner

View Archive